Our Science

Our Science

Pioneering the unseen.

Our comprehensive investigation into the pathophysiology of androgenic alopecia has revealed a range of complex mechanisms contributing to hair loss and thinning.
In response, we focused on the development of targeted molecules designed to address each of these mechanisms individually.
Each molecule underwent extensive preclinical and clinical testing to confirm
both efficacy and safety, with the results published in 2024.

A human clinical trial, conducted with rigorous controls, demonstrated a statistically significant increase in hair count when compared to the placebo group.
TrinogeniX™, a proprietary blend of three patented ingredients, offers a scientifically backed solution that delivers tangible and lasting results.

Development History

2022~2024

2021~2022

2021

TrinogeniX™ in detail and its clinical benefits

TrinogeniX™ in detail and its clinical benefits

Renovodole : Fill
Renovodole, an inhibitor of prostaglandin degrading enzyme (15-prostaglandin dehydrogenase), stimulates hair regeneration by activating hair follicle stem cells with increasing prostaglandin E2 (PGE2) concentration.

Renovozol, a GPR44 antagonist, stimulates hair growth by elongating anagen period with blocking the action of prostaglandin D2 (PGD2), which is known to inhibit hair growth.

Renovoridine, a glycogen phosphorylase enzyme inhibitor, stimulates hair growth by inhibiting catagen entry with modulating energy metabolism and blocking reactive oxygen species (ROS).